Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Updated May 2026 · ClinicalTrials.gov

Phase 3 Thyroid Trials

7 Phase 3 trials for Thyroid, the final stage before a treatment can be submitted for FDA approval.

7 Phase 3 clinical trials for Thyroid are registered on ClinicalTrials.gov. Phase 3 is the final stage of testing before a treatment can be submitted for FDA approval, and the trials below come directly from the federal registry. Always talk to your doctor before contacting a study site.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

What Phase 3 Means for Thyroid

Phase 3 trials are the largest and most expensive stage of clinical research before potential FDA approval. For Thyroid, a Phase 3 protocol typically enrolls several hundred to several thousand patients across many medical centers, randomizes participants between the investigational treatment and either a placebo or current standard of care (where ethically appropriate), and tracks them for months or years to confirm that the treatment is both effective and safe in a real-world patient population.

7 Phase 3 trials for Thyroid are listed on ClinicalTrials.gov. Smaller late-stage pipelines often correspond to rare conditions, niche subpopulations, or treatment areas where Phase 2 results are still being read out.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1), Minghui Pharmaceutical (Hangzhou) Ltd (1), Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) lead the Phase 3 Thyroid sponsor list. The blend of industry, academic, and government sponsors on a condition's Phase 3 list is a useful signal of how broadly the research community is engaged with the disease.

Phase 3 Thyroid Trials on ClinicalTrials.gov

RECRUITINGPhase 3NCT06860971

A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid...

This study aims to demonstrate that, in subjects with locally advanced or metastatic iodine - refractory differentiated thyroid cancer who have failed previous VEGFR - targeted...

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Enrolling: 14420 locations
RECRUITINGPhase 3NCT06989918

MHB018A Treatment in Patients With Active Thyroid Eye Disease

The primary objective of this study is to investigate the efficacy, safety, and tolerability of MHB018A, a humanized anti-IGF1R antibody, administered q4W for 6 months, in...

Sponsor: Minghui Pharmaceutical (Hangzhou) LtdEnrolling: 1081 location
RECRUITINGPhase 3NCT07383246

CTR-FAPI-guided Precision Surgery for Newly Diagnosed MTC

This is a multicenter, randomized, open-label, non-inferiority Phase III clinical trial, aims to compare 68Ga-CTR-FAPI PET-CT-guided surgery to investigator-chosen surgical...

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical SciencesEnrolling: 1501 location
RECRUITINGPhase 3NCT06558981

Adjuvant Radiotherapy in High Risk Locally Advanced DTC

This study is a phase III randomized controlled clinical trial on the role of adjuvant radiotherapy in high-risk locally advanced differentiated thyroid cancer. Patients who meet...

Sponsor: Fudan UniversityEnrolling: 1241 location
RECRUITINGPhase 3NCT06475989

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

This phase III trial compares the effect of cabozantinib versus combination dabrafenib and trametinib for the treatment of patients with differentiated thyroid cancer that does...

Sponsor: ECOG-ACRIN Cancer Research GroupEnrolling: 26420 locations
RECRUITINGPhase 3NCT04856488

Preoperative Lugol's Solution in Graves' Disease and Toxic Nodular Goiter

The purpose of this study is to assess if preoperative treatment with Lugol's solution prior to thyroidectomy can reduce the surgical complications hypoparathyroidism and...

Sponsor: Jan CalissendorffEnrolling: 1821 location
RECRUITINGPhase 3NCT07211776

A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease

A Multicenter, Double-blinded, Randomized, Placebo-controlled Phase 3 Study of ZL-1109 in Chinese Participants with Thyroid Eye Disease (TED)

Sponsor: Zai Lab (Shanghai) Co., Ltd.Enrolling: 9920 locations

What Participation Looks Like

Phase 3 trials for Thyroid typically enroll several hundred to several thousand participants across multiple sites. Participation involves a screening visit to confirm eligibility, randomization to either the investigational treatment or a comparator (often the current standard of care), regular study visits over months or years, and follow-up after the active treatment period. The protocols, time commitments, and visit schedules differ from trial to trial — read the per-trial page for the specifics before discussing participation with your doctor.

Each trial begins with informed consent and a screening visit, where the study team confirms eligibility against the inclusion and exclusion criteria. Randomization assigns participants to either the investigational treatment or a comparator. Standard-of-care portions of the protocol are typically billed to insurance; trial-specific procedures (extra imaging, biopsies, lab draws beyond standard care) are usually covered by the sponsor. Read each trial\'s detailed page for its specific time commitment and visit schedule.

Authoritative Resources for Thyroid Trials

Verify any individual trial directly on ClinicalTrials.gov. For the federal context on how Phase 3 results feed into approval decisions, see the FDA drug approval process. For oncology-specific trial resources, the National Cancer Institute publishes patient-oriented overviews. For trials registered outside the U.S., the WHO ICTRP aggregates registries from around the world.

Frequently Asked Questions

What is a Phase 3 Thyroid trial?

A Phase 3 trial is the final stage of clinical testing before a treatment can be submitted to the FDA for approval. For Thyroid, Phase 3 studies typically enroll hundreds to thousands of patients across multiple medical centers, comparing the new treatment to the current standard of care or a placebo (where ethically appropriate). The goal is to confirm efficacy, monitor side effects in a larger population, and generate the evidence the FDA needs to make an approval decision.

How many Phase 3 Thyroid trials are recruiting?

7 Phase 3 trials for Thyroid are currently registered on ClinicalTrials.gov. Recruitment status varies by trial — some are actively enrolling, some have closed enrollment but are still in the active treatment phase, and some are completing follow-up. Click any trial below to see its current status, eligibility criteria, and contact information.

Who can participate in a Phase 3 Thyroid trial?

Phase 3 eligibility depends entirely on the specific trial protocol. Each trial sets its own inclusion criteria (typically a confirmed diagnosis, certain disease stage or severity, age range) and exclusion criteria (often previous treatments, comorbidities, lab values that fall outside set ranges). The trial pages on this site translate the clinical eligibility criteria into plain English alongside the original text. Whether you fit any specific trial is a medical decision your doctor needs to confirm.

Is participating in a Phase 3 Thyroid trial safe?

Phase 3 trials use treatments that have already passed Phase 1 (safety in small groups) and Phase 2 (initial efficacy and side-effect monitoring), so the safety profile is better understood than in earlier-phase studies. That said, side effects can still emerge in larger populations, and the trial protocol may require additional procedures (lab draws, imaging, biopsies) beyond standard care. The informed consent document for any specific trial details the known risks. Discuss those risks with your physician before deciding whether to participate.

Where does this trial data come from?

All trial data is sourced from the ClinicalTrials.gov API v2, the federal registry maintained by the National Library of Medicine at NIH. Under FDAAA 801, most U.S. drug and device trials must register on ClinicalTrials.gov, making it the most comprehensive source of trial information. Sponsors are required to update trial status within 30 days of a change, but delays occur — always confirm the current status with the trial site before traveling for screening.

How This Page Is Built

The trial list is filtered to ClinicalTrials.gov registrations whose phase field includes Phase 3 and whose condition list includes Thyroid. Trial counts and the sponsor leaderboard are computed from the same record set. Plain-English eligibility translations on each linked trial page preserve the original clinical text alongside the accessible version. Read the full methodology for the data pipeline and known limitations.

Source: ClinicalTrials.gov API v2, maintained by the National Library of Medicine at NIH. Public domain. Cite as: "TrialFinderData, Phase 3 Thyroid list, May 2026. Data: ClinicalTrials.gov."

Medical disclaimer: This page is informational, not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Last updated 2026-05-08 · 7 Phase 3 trials tracked for Thyroid.

The this entity category groups every U.S. clinical trials and research registries entity sharing this attribute. The list above is the data; the paragraphs below explain what the grouping means against the broader the NIH ClinicalTrials.gov registry distribution and how to read the relative rankings within the category.

For readers using this category as a starting point, the per-entity detail pages linked from the table above carry the underlying the NIH ClinicalTrials.gov registry data in full. The category-level view is the filter; the per-entity pages are the actual answer.